Shionogi successfully completes tender offer for Torii Pharmaceutical shares

Shionogi & Co., Ltd. (TSE:4507) announced the successful completion of its tender offer for shares of Torii Pharmaceutical Co., Ltd. (TSE:4551), initiated on May 7, 2025. With 10,977,091 shares tendered, exceeding the minimum requirement of 3,342,000 shares, Shionogi will purchase all tendered shares for JPY 6,350 per share, totaling JPY 69.704 billion. This acquisition will make Torii Pharmaceutical an equity-method affiliate of Shionogi, effective June 25, 2025. As a result, Shionogi intends to implement procedures to make the Tender Offer Related Parties the only shareholders of Torii Pharmaceutical. Consequently, Torii Pharmaceutical's stock, currently listed on the Prime Market of the Tokyo Stock Exchange, will be delisted following exchange procedures, after which trading will no longer be possible. Post-acquisition, Shionogi will hold 10,977,092 shares of Torii, representing 39.04% of voting rights. Shionogi is currently assessing the impact of this change on its consolidated financial results and will promptly disclose any relevant information.